ClinicalTrials.gg
Not yet recruitingNCT07946549Updated Nov 18, 2026

A Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia

A Phase 2 interventional study of CID-103 in Chronic Immune Thrombocytopenia, sponsored by CASI pharmaceuticals, Inc.. Not yet recruiting at 11 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by CASI pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 187 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China — 84 open to participants now, 94 under way, 12 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · China.

Planned enrollment
98th of 169
54 · median 60
Started
2026
with 20 others
Phase 2
66 of 187
34 open now
Primary completion
2028-11
later than 87 of 93 live
Registered
187th of 187
by date

Among the 187 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China, this one is the 98th largest by planned enrollment of the 169 interventional ones that give a count, is one of 21 that started in 2026, is one of 66 in phase 2, reaches primary completion later than 87 of the 93 other live ones, and was the 187th registered.

Purpura, Thrombocytopenic, Idiopathic

505 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 160 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

84 of the 187 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China are open now. Recruiting first, the newest first:

79 more — sign in →

All 84 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 104 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (47%) set no upper age limit and 43 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China, or all of them as a file.
02

Study summary

The goal of the global Phase 1/2 clinical trial is to evaluate whether CID-103, a novel anti-CD38 monoclonal antibody, is safe and effective in adults with chronic immune thrombocytopenia (ITP). The main questions the study aims to answer are:

  • To evaluate the safety and tolerability of CID-103 in subjects with ITP with different increasing doses of CID-103.
  • To further evaluate the safety and tolerability of CID-103 at two or three dose levels and to select an optimal dose and administration regimen for CID-103 for further study of clinical efficacy.

The study will be done in two parts:

Part A will test increasing doses of CID-103 to see how safe it is and how well people tolerate it. Researchers will also aim to find a safe dose range.

Part B will compare up to three different doses of CID-103 to see how well the medicine works and gather more safety and efficacy information. The goal is to find the optimal dose to use in future studies.

CID-103 is given through an intravenous (IV) infusion. During the study, participants may receive treatment for up to 6 months, followed by a post-treatment safety follow-up period to check for ongoing safety and effectiveness.This study is an important step toward developing a new treatment for people living with chronic ITP. If CID-103 is found to be safe and effective, it could offer a new option for patients who do not respond well to current therapies.

Read the detailed description

The enrollment of participants in part A has been completed (ClinicalTrials.gov ID: NCT07017725). Totally 23 participants have been enrolled. Three CID-103 doseages including 600mg, 900mg, and 1200mg have been proposed for part B for further evaluation.

This is Part B study, it will compare 600mg, 900mg, and 1200mg doses of CID-103 to see how well the medicine works and gather more safety and efficacy information. The goal is to find the optimal dose to use in future studies.

03

Conditions studied

  • Chronic Immune Thrombocytopenia

Keywords

  • Chronic Immune Thrombocytopenia persisted for ≥ 3 months
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female individuals aged 18 to 65 years at time of signing of ICF.
  2. Diagnosed with ITP that has persisted for ≥ 3 months, diagnosed in accordance with The American Society of Hematology 2019 Guidelines for Immune Thrombocytopenia or the Updated International Consensus Report on the Investigation and Management of Primary Immune Thrombocytopenia (as locally applicable).
  3. Diagnosis of ITP supported by a prior response to an ITP treatment (other than a thrombopoietin receptor agonists [TPO-RA]) that achieved a count of ≥ 30 x 10\^9/L and a doubling of baseline measurement.
  4. Has received at least two lines of SOC systemic treatment (i.e., and one other agent).

    Note: Subjects who have received one and who are currently receiving a second line of treatment are also considered eligible Exceptions: Subjects who are intolerant of SOC treatment or subjects who do not have access to SOC treatment; approval from Medical Monitor is required.

  5. Has a mean platelet count ≤ 35 x 10\^9/L on at least two measurements at least one week apart during screening.
  6. If receiving standard background treatment for ITP, treatment should be stable in dose and frequency for at least four weeks prior to first dose of CID-103.

    Note: Permitted standard background treatments for ITP may include:

    • one oral corticosteroid with or without up to two of the following
    • one from the following list: azathioprine, danazol, dapsone, cyclosporine, mycophenolate mofetil, mycophenolate sodium
    • one TPO-RA (romiplostim, eltrombopag, avatrombopag) administered at standard therapeutic doses for at least four weeks
    • fostamatinib.
  7. Adequate organ function
  8. : Female participants must either be non-pregnant or not breastfeeding and must have a negative pregnancy test. Male and female participants must meet the contraceptive requirements.

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with any anti-CD38 agent, or has been treated with anti-Bruton's tyrosine kinase (BTK), neonatal Fc receptor (FcRn) antagonist or complement inhibitor within three months prior to first dose of CID-103.
  2. Use of intravenous (IV) immunoglobulin, subcutaneous immunoglobulin or anti-D immunoglobulin treatment within four weeks of screening.
  3. IgG \< 300 mg/dL
  4. Use or expected immediate use of rescue therapy for an active hemorrhage, high risk of bleeding or critically low within two weeks prior to first dose of CID-103.
  5. More than a 10% variation in and/or TPO-RA dose within two weeks prior to first dose of CID-103
  6. Treatment with rituximab or splenectomy within the three months prior to first dose of CID-103.
  7. Use of anticoagulants or any drug with antiplatelet effect (such as aspirin) within three weeks before screening.
  8. drugs other than corticosteroids and those outlined in inclusion criterion #6.

    Note: These drugs should be discontinued for at least 14 days before first dose of CID-103.

  9. Receiving other concurrent therapies or have received investigational therapies within four weeks of the first dose of CID-103 or five half-lives (if shorter).
  10. Active hemolytic anemia.
  11. Diagnosed with severe (COPD), Global Initiative for Chronic Obstructive Lung Disease (GOLD Stage 3 or 4) or asthma, and a pre-bronchodilator (FEV1) \< 50% of predicted normal.
  12. Has been diagnosed with myelodysplastic syndrome or other active .
  13. Known / amyloidosis.
  14. Requires renal dialysis.
  15. Has a history of any thrombotic or embolic event within six months before screening.
  16. A history or evidence of cardiovascular risk including any of the following:

    1. Current \< 50%
    2. A history or evidence of current clinically significant uncontrolled ventricular arrhythmia. Subjects with atrial fibrillation controlled for > 30 days prior to first dose of CID-103 are eligible.
    3. A history of acute coronary syndrome (including myocardial infarction or unstable angina), coronary angioplasty or stenting within six months prior to first dose of CID-103
    4. A history or evidence of current ≥ Class III congestive heart failure as defined by the (NYHA) guidelines
    5. Treatment hypertension defined as a blood pressure of systolic > 160 mmHg and/or diastolic > 100 mmHg which cannot be controlled by anti-hypertensives.
  17. History or clinical evidence of any surgical or medical condition which the Investigator judges as likely to interfere with the results of the study or pose an additional risk in participating, particularly any pre-existing condition that would put the subject at additional risk should they experience an IRR
  18. Any unresolved treatment-related AE(s) from prior treatment that have not resolved to Grade 1 or baseline value prior to first dose of CID-103.
  19. Active infection requiring systemic therapy.
  20. Known to CID-103 or prior severe hypersensitivity to a monoclonal antibody.
  21. History of severe recurrent or chronic infections, or acute infections requiring systemic treatment with antibiotics, antiviral drugs, antiparasitic drugs, anti-amoebic drugs, or antifungal drugs within four weeks prior to the first dose of CID-103 and during the screening period, or superficial skin infections requiring systemic treatment within one week prior to the first dose of CID-103.
  22. History of known or suspected immunosuppression, including invasive opportunistic infections such as histoplasmosis, listeriosis, coccidioidomycosis, pneumocystis pneumonia, and aspergillosis, even if the infection has resolved; or unusually frequent, recurrent, or prolonged infections (as judged by the Investigator).
  23. Known active infection with (HIV) and \< 350/μL.
  24. Known active infection with (HBV) (surface antigen) or infection with (HCV) in absence of sustained virologic response.
  25. At the time of signing is a regular user (including "recreational / medical use") of any illicit drugs or had a recent history (within the last year) of substance abuse (including alcohol). If a subject agrees to abstain for the duration of the study and is for a month prior to first dose of CID 103, they may be considered for enrollment in the trial at the discretion of the Investigator in agreement with the Medical Monitor.
  26. Performance Status ≤ 70
  27. Inability to perform study baseline RBC type and cross-match, phenotype (and genotype, if applicable) or lack of available baseline data on RBC phenotype (or genotype, if applicable).
  28. Unable or not willing to agree to the evaluation of RBC antigens by phenotyping or genotyping.
  29. Unable or not willing to sign the ICF and comply with the protocol and the restrictions and assessments therein.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
54 participants (estimated)

Study arms

  • Experimental
    CID-103 1200mg

    Following an initial priming dose of 150 mg on Week 1, participants will receive CID-103 at dose 1200mg administered.

    Drug: CID-103

  • Experimental
    CID-103 900mg

    Following an initial priming dose of 150 mg on Week 1, participants will receive CID-103 at dose 900mg administered.

    Drug: CID-103

  • Experimental
    CID-103 600mg

    Following an initial priming dose of 150 mg on Week 1, participants will receive CID-103 at dose 600mg administered.

    Drug: CID-103

Interventions

  • Strength:20 mg/mL. Route of administration: IV infusion. Treatment duration: QW for 6 weeks, then at the same dose Q2W up to Week 12. If treatment continues after Week 12, dosing will occur monthly for up to a maximum treatment duration of 6 months.

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of CID-103, Frequency of TEAEs

    Frequency of TEAEs

    Time frame: 10 months

  2. Safety and tolerability of CID-103, Related AEs

    Related AEs

    Time frame: 10 months

  3. Safety and tolerability of CID-103, Grade 3/4 AEs

    Grade 3/4 AEs

    Time frame: 10 months

  4. Safety and tolerability of CID-103, Serious adverse events (SAEs)

    Serious adverse events (SAEs)

    Time frame: 10 months

  5. Safety and tolerability of CID-103, Fatal AEs

    Fatal AEs

    Time frame: 10 months

  6. Safety and tolerability of CID-103, AEs leading to CID-103 discontinuation

    AEs leading to CID-103 discontinuation up to Week 12

    Time frame: 12 weeks

  7. Safety and tolerability of CID-103

    Percentage of participants with at least one treatment-related Grade ≥ 3 TEAE, SAE or AE leading to CID-103 discontinuation up to Week 12

    Time frame: 12 weeks

  8. Platelet response

    A platelet count ≥ 50 x 10\^9/L and ≥ 20 x 10\^9/L above baseline achieved on at least two consecutive measurements at least seven days apart.

    Time frame: 12 weeks

Secondary outcomes

  1. Platelet count

    The secondary efficacy endpoint is Platelet count, defined as platelet count ≥ 30 x 10\^9/L and \> 2-fold increase in platelet count from baseline and absence of bleeding requiring medical intervention / treatment, measured on at least two consecutive occasions at least seven days apart.

    Time frame: 12 weeks

  2. Complete platelet response

    The secondary efficacy endpoint includes percentage of participants with complete platelet response, defined as platelet count ≥ 100 x 10\^9/L and absence of bleeding requiring medical intervention / treatment, measured on at least two consecutive occasions at least seven days apart.

    Time frame: 12 weeks

07

Study locations

11 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2028, 24 months later.

Of 66 phase 2 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 41. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 18, 2026
StartEst.
Nov 30, 2026
Primary completionEst.
Nov 30, 2028
CompletionEst.
Jan 31, 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07946549
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Nov 30, 2026 (estimated)
Primary completion
Nov 30, 2028 (estimated)
Completion
Jan 31, 2029 (estimated)
Last update
Nov 18, 2026

Study contacts

Aaron Yang
Contact
aarony@casi.cn
+86 10 6561 8789
Hao Zhang
Contact
haoz@casi.cn
+86 10 6561 8789
Junping Chen
study chair · CASI pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CID-103

Start the discussion